![Jack Higgins](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jack Higgins
Hoofd Techniek/Wetenschap/O&O bij IMMUNOME, INC.
Vermogen: - $ op 31-05-2024
Profiel
Jack Higgins is currently the Chief Scientific Officer at Immunome, Inc. He previously worked as the Chief Development Sciences Officer at Molecular Templates, Inc. from 2010 to 2021 and again from 2019 to 2021.
He also served as the Chief Scientific Officer at MorphImmune, Inc. from 2022 to 2023.
Dr. Higgins obtained his undergraduate degree from Texas A&M University and his graduate and doctorate degrees from The University of Arkansas.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
IMMUNOME, INC.
-.--% | 01-04-2024 | 0 ( -.--% ) | - $ | 31-05-2024 |
Actieve functies van Jack Higgins
Bedrijven | Functie | Begin |
---|---|---|
IMMUNOME, INC. | Hoofd Techniek/Wetenschap/O&O | 02-10-2023 |
Eerdere bekende functies van Jack Higgins
Bedrijven | Functie | Einde |
---|---|---|
MorphImmune, Inc.
![]() MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Hoofd Techniek/Wetenschap/O&O | 01-10-2023 |
Molecular Templates, Inc. /Old/
![]() Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Operationeel Directeur | 01-06-2019 |
MOLECULAR TEMPLATES, INC. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Jack Higgins
The University of Arkansas | Doctorate Degree |
Texas A&M University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
MOLECULAR TEMPLATES, INC. | Health Technology |
IMMUNOME, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Molecular Templates, Inc. /Old/
![]() Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Health Technology |
MorphImmune, Inc.
![]() MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Health Technology |